Evommune, Inc. (NYSE:EVMN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Evommune, Inc. (NYSE:EVMN) have received an average recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $41.5556.

A number of analysts have recently issued reports on the stock. Weiss Ratings cut shares of Evommune from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. Morgan Stanley lowered their price target on shares of Evommune from $55.00 to $26.00 and set an “overweight” rating on the stock in a report on Tuesday, June 30th. Wall Street Zen downgraded shares of Evommune from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Royal Bank Of Canada reduced their price objective on Evommune from $30.00 to $29.00 and set an “outperform” rating for the company in a report on Friday, August 7th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Evommune in a research report on Monday, August 3rd.

Insider Transactions at Evommune

In other news, Director Arthur S. Kirsch bought 10,000 shares of the company’s stock in a transaction dated Tuesday, July 7th. The stock was bought at an average price of $13.30 per share, with a total value of $133,000.00. Following the completion of the acquisition, the director owned 10,000 shares of the company’s stock, valued at $133,000. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Jeegar Pravinkumar Patel sold 1,488 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $22.50, for a total transaction of $33,480.00. Following the completion of the sale, the insider directly owned 46,403 shares of the company’s stock, valued at approximately $1,044,067.50. The trade was a 3.11% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 28,926 shares of company stock valued at $654,997. Corporate insiders own 31.10% of the company’s stock.

Institutional Trading of Evommune

A number of institutional investors have recently bought and sold shares of the business. Strs Ohio acquired a new position in shares of Evommune during the 1st quarter worth approximately $41,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Evommune in the fourth quarter valued at approximately $179,000. The Manufacturers Life Insurance Company boosted its stake in shares of Evommune by 25.3% in the first quarter. The Manufacturers Life Insurance Company now owns 12,812 shares of the company’s stock valued at $295,000 after buying an additional 2,587 shares during the period. XTX Topco Ltd bought a new stake in shares of Evommune in the fourth quarter valued at approximately $321,000. Finally, Oxford Asset Management LLP acquired a new stake in Evommune during the fourth quarter worth approximately $335,000.

Evommune Stock Down 1.6%

EVMN opened at $12.46 on Wednesday. Evommune has a 12-month low of $10.47 and a 12-month high of $33.20. The business has a 50 day moving average of $13.60 and a 200-day moving average of $20.46. The stock has a market cap of $452.17 million and a price-to-earnings ratio of -1.13.

Evommune (NYSE:EVMN) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.21). As a group, analysts expect that Evommune will post -3.16 earnings per share for the current year.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.